B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Leukemia trial pulled before it started: safer transplant prep remains untested
Disease control TerminatedThis trial was designed to test a milder conditioning regimen using a radioactive antibody (90Y-Epratuzumab) followed by chemotherapy and a stem cell transplant for adults with CD22-positive B-cell acute lymphoblastic leukemia. The goal was to find the safest dose that still cont…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take aim at stubborn childhood leukemia
Disease control OngoingThis phase II trial tests a personalized cell therapy called tisagenlecleucel (Kymriah) in children and young adults with high-risk B-cell acute lymphoblastic leukemia who still have detectable cancer cells after initial chemotherapy. The treatment involves collecting the patient…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at returning blood cancers
Disease control OngoingThis early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Engineered immune cells take on stubborn leukemia
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified to find and attack cancer cells that carry a marker called CD19. It is for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The goal is to see …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New 'Sandwich' strategy aims to stop leukemia relapse after CAR-T
Disease control TerminatedThis phase 2 trial tests a new treatment plan for teenagers and adults with B-cell acute lymphoblastic leukemia. Patients receive immunotherapy before a stem cell transplant using their own cells, followed by a CD22/CD19 CAR-T 'sandwich' to reduce the risk of relapse. The study a…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New 'Sandwich' strategy aims to stop leukemia relapse
Disease control OngoingThis study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses a 'sandwich' strategy: first, patients receive two types of CAR T-cells (targeting CD22 and CD19), th…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for adults with rare leukemia: drug combo shows promise in early trial
Disease control OngoingThis early-phase trial is testing whether adding the drug venetoclax to a chemotherapy regimen originally designed for children can be safe and effective for adults aged 18-54 with a specific, aggressive form of B-cell acute lymphoblastic leukemia (Ph-like ALL). The study will en…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Gentler chemo combo shows promise for older leukemia patients
Disease control OngoingThis study tests a drug called blinatumomab, given as a shot under the skin, combined with low-intensity chemotherapy for people aged 60 and older (or younger adults who are not healthy enough for strong chemo) with B-cell acute lymphoblastic leukemia. The goal is to see if this …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Off-the-Shelf CAR-T cells take on tough blood cancers
Disease control TerminatedThis early-phase trial tests a universal (donor-derived) CAR-T cell therapy called UWD-19 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. Up to 30 participants will receive a single infusion of these cells after chemotherapy, along wi…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Engineered t cells take aim at Hard-to-Treat leukemia
Disease control OngoingThis early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse th…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a One-Time immune cell infusion help older leukemia patients avoid harsh chemo?
Disease control OngoingThis early-phase trial tests a personalized cell therapy for adults aged 60 and older with B-cell acute lymphoblastic leukemia (ALL) who are in first remission. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack leukemia cells, and infus…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Off-the-Shelf cell therapy takes on tough blood cancers
Disease control OngoingThis early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug aims to wipe out lingering leukemia cells after chemo
Disease control OngoingThis phase 2 trial tests the drug inotuzumab ozogamicin in 31 adults with B-cell acute lymphoblastic leukemia (ALL) who achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells detectable (called minimal residual disease, or MRD). The goal is to…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control OngoingThis early-phase trial is testing a new treatment called MB-CART19.1 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better r…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Boosting CAR t: early second dose may keep childhood leukemia at bay
Disease control OngoingThis study tests whether giving a second dose of the CAR T-cell therapy tisagenlecleucel early can keep the immune system's B cells low for at least 6 months in children and young adults with relapsed B-cell acute lymphoblastic leukemia. The goal is to reduce the chance of the ca…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo shows promise in early trial for tough blood cancer
Disease control OngoingThis early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL), a fast-growing blood cancer. About 23 adults whose cancer has returned or not responded to treatment …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells target tough blood cancers in new trial
Disease control OngoingThis study tests FDA-approved CAR-T cell therapy in 150 children and adults with certain blood cancers that have come back or not responded to treatment. Participants receive their own immune cells that have been reprogrammed to attack cancer cells. The goal is to see how many pa…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on childhood leukemia in early trial
Disease control OngoingThis study tests a one-time treatment using the patient's own immune cells, modified to target a protein called CD22 on leukemia cells. It is for children and young adults whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The main goa…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Real-World data shows promise for CNCT-19 in tough leukemia
Disease control OngoingThis study looks at how well a treatment called CNCT-19 works for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL). Researchers will review medical records from 275 patients across multiple hospitals in China to see how many achieve remission an…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered t cells take on tough leukemia in early trial
Disease control OngoingThis early-stage study tests a new cell therapy for adults with a hard-to-treat type of leukemia (ALL). Doctors take a patient's own white blood cells, add a special gene to help them find and kill cancer cells, and give them back after chemotherapy. The main goals are to check s…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Engineered immune cells take on childhood leukemia and lymphoma
Disease control OngoingThis study is testing a therapy where a child's own immune cells are modified in a lab to recognize and attack cancer cells. The treatment is for children with B-cell acute lymphoblastic leukemia or certain types of lymphoma that have come back or not responded to standard treatm…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Engineered immune cells take on tough leukemia
Disease control OngoingThis early-stage trial tests a new approach for adults with acute lymphoblastic leukemia that has not responded to chemotherapy. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack cancer cells with CD22 and CD19 proteins, and infuse them…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo aims to tame CAR T-Cell side effects in leukemia
Disease control OngoingThis early-phase trial tests whether adding pulses of the cancer drug dasatinib to standard CAR T-cell therapy (brexucabtagene autoleucel) is feasible and safe for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Eight participants receive dasatinib on a we…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control OngoingThis early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental combo therapy aims to outsmart leukemia without dangerous side effects
Disease control OngoingThis early-stage trial tests whether giving specially engineered donor immune cells (CAR T cells) along with a special stem cell transplant (Orca-T) is safe for adults with a high-risk type of leukemia called B-cell ALL. The approach is designed to help the donor cells attack the…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 26, 2026 18:00 UTC
-
Researchers look back at leukemia Drug's Real-World results
Knowledge-focused OngoingThis study looks back at the medical records of 102 adults with B-cell acute lymphoblastic leukemia who received the drug inotuzumab ozogamicin. The goal is to see how well the drug worked and how safe it was. No new treatments are given; researchers are just gathering existing d…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC